Developer docs
API playgroundTry for free, no card

Search company profiles

BioFluidica

Full company profile

uuid0002pyg

Namestring
BioFluidica
Legal namestring
BioFluidica, Inc.
Websiteurl
biofluidica.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

BioFluidica is a privately held biotechnology company that has developed the LiquidScan® platform, a microfluidics-based liquid biopsy system that isolates and enriches rare cells — including circulating tumor cells (CTCs) and fetal trophoblasts — and exosomes/extracellular vesicles from whole blood, plasma, urine, and saliva. The platform centers on proprietary antibody-surfaced microfluidic chips (sinusoidal for rare-cell capture, pillar for exosome subpopulations) combined with a catch-and-release chemistry using photoactivated (415 nm) or heat-activated enzymatic cleavable linkers, integrated onto Hamilton Microlab STAR/STARlet liquid handling robots via proprietary automation software.

The company sells three product lines: LiquidScan instruments installed at customer facilities, one-time-use consumable microfluidic chips and reagent kits (4- or 8-chip formats), and fee-for-service testing from its San Diego Core Lab. Pricing is quote-based and not publicly disclosed. Its primary customer segments are oncology researchers and clinicians (covering nine-plus cancer types including ovarian, colorectal, lung, pancreatic, and leukemia) and prenatal diagnostics researchers pursuing cell-based NIPT, with secondary reach into academic research institutions and immunotherapy developers. Named customers include the University of Kansas Medical Center, which has run LiquidScan systems continuously since 2022.

BioFluidica operates from three U.S. locations: a world headquarters in Cary, North Carolina; the Central Innovation Lab in Lawrence, Kansas; and a San Diego Core Facility. Leadership includes Co-Founder and CTO Dr. Steven A. Soper (Foundation Distinguished Professor at Kansas University, 310+ peer-reviewed publications, three-time NAI Fellow) and CEO Greg Studdard (former executive at GeneCare/Alere and Verinata Health, which was acquired by Illumina in 2013). The company raised over $6 million in a Series B2 round in February 2022 (with closings anticipated to $10M) and received MBArC/NIH RADx Tech grant funding to extend the platform toward handheld at-home disease testing. LiquidScan is currently labeled for Research Use Only; no FDA-cleared clinical diagnostic product has been disclosed.

Short descriptiontext

BioFluidica is a privately held biotechnology company that has developed the LiquidScan microfluidics-based liquid biopsy platform, which isolates and enriches rare cells and exosomes from bodily fluids for oncology and prenatal diagnostics researchers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
liquid biopsy platform, microfluidic diagnostics, rare cell isolation, exosome isolation, circulating tumor cells
Industry3 codes
PRIMARYHLAAAMAH
Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAHAAAN
Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHDAHALAK
Biosensors & Lab-on-Chip (BioMEMS)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical Laboratories621511
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code3 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Surgical & Medical Instruments & Apparatus3841
  • Services-Medical Laboratories8071
Product category
Liquid Biopsy Diagnostics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1LiquidScan Instrument Sales
TypeOne Time License
Description

Sale of LiquidScan processing module and reagent kits for installation in customer facilities (research institutions, clinical labs). The system is sold with associated microfluidic chips and reagents.

biofluidica.com
2Fee-for-Service Testing
TypeProfessional Services
Description

BioFluidica offers services from their Core Labs on a fee-for-service basis, performing complete studies or pilot projects for customers who prefer not to operate their own systems.

biofluidica.com
3Reagent Kit Sales
TypeHardware Sales
Description

Sale of reagent plates, microfluidic chips (4 or 8 per kit), sample tubes, and waste tubes. Reagent kits are one-time-use consumables that must be repurchased for each run.

biofluidica.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
Pricing details3 tiers
1LiquidScan System - For installation in customer facilities
ModelOne time/ perpetual licenseBilling cadenceMulti-year contract
Notes

Contact BioFluidica for pricing. System integrates with Hamilton Microlab STARlet or STAR liquid handling robot.

biofluidica.com
2Fee-for-Service Core Lab Testing
ModelOtherBilling cadencePay-as-you-go
Notes

Fee-for-service pricing available upon consultation. BioFluidica performs studies or pilot projects in their Core Labs.

biofluidica.com
3Reagent Kits (4 or 8 chips)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

One-time-use test-specific consumables; pricing requires inquiry.

biofluidica.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1LiquidScan®
Description

A fully-automated liquid biopsy platform for isolating and enriching rare cells (CTCs, trophoblasts) and exosomes from liquid biopsy samples using microfluidic chip technology.

biofluidica.com
Core offering1 text field

BioFluidica develops and sells the LiquidScan® platform, a fully automated microfluidic system for isolating and enriching rare cells (circulating tumor cells, fetal trophoblasts) and exosomes from liquid biopsy samples including whole blood, plasma, urine, and saliva. The platform pairs proprietary antibody-surfaced microfluidic chips with a Hamilton Microlab STAR/STARlet liquid handling robot and uses catch-and-release cleavable-linker chemistry to release intact analytes compatible with downstream molecular analysis. The company also offers reagent kits, one-time-use microfluidic chips, and fee-for-service testing from its San Diego Core Lab.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Captures rare cells at concentrations of 1-10 CTCs/ml in blood with high efficiency
+3 more records
Product overview1 text field

BioFluidica offers the LiquidScan® platform as its core product line, comprising an automated system (LiquidScan STAR(let)) that processes one-time-use microfluidic chips and reagent kits to isolate and enrich rare cells (CTCs, trophoblasts) and exosomes from liquid biopsy samples. The platform supports whole blood, plasma, urine, and saliva samples and produces output compatible with downstream molecular analysis methods including NGS, RNA-Seq, ddPCR, and qPCR. Additionally, BioFluidica is developing a Fetal Cell-Based DNA Test for prenatal diagnostics.

Product and service4 records
1LiquidScan Automated System
CategoryLiquid biopsy instrumentation
Description

Fully automated walk-away system for isolating and enriching rare cells and exosomes from liquid biopsy samples (whole blood, plasma, urine, saliva). Integrates with a Hamilton Microlab STAR or STARlet liquid handling robot and uses proprietary antibody-surfaced microfluidic chips with catch-and-release cleavable-linker chemistry. Used by oncology and prenatal researchers, academic core facilities, and pharmaceutical R&D teams.

2LiquidScan Microfluidic Chips
CategoryConsumables
Description

One-time-use test-specific microfluidic devices with antibody-surfaced channels for capture, isolation, and enrichment of rare cells or exosomes. Available in sinusoidal (rare-cell) and pillar (exosome) chip formats. Chips can process 1-8 simultaneously. Sold as part of reagent kits to customers operating the LiquidScan system.

3LiquidScan Reagent Kits
CategoryConsumables
Description

Reagent plate with contents ready to process 4 or 8 microfluidic chips, including antibody-surfaced chips, sample tubes, and waste/re-process sample tubes. One-time-use test-specific consumables that must be repurchased for each run.

4Fee-for-Service Core Lab Testing
CategoryService
Description

BioFluidica performs complete studies or pilot projects on a fee-for-service basis from its San Diego Core Facility for customers who prefer not to operate their own LiquidScan systems. Offers whole-blood, plasma, urine, and saliva sample processing for rare cell and exosome isolation.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

BioFluidica equipped the liquid biopsy core facility at KUMC with LiquidScan systems to serve their clinical research needs. The systems have been continuously operating since 2022, testing applications and evolving user protocols. This partnership enables clinical validation and provides reference site for technology demonstration.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Offers the CELLSEARCH CTC system and DEPArray for rare-cell isolation and downstream molecular analysis; directly competes with BioFluidica in circulating tumor cell capture and downstream characterization for liquid biopsy research and clinical use.

TypeDirect peer
Description

Provides microfluidic and magnetic-bead-based cell separation platforms (e.g., MACS, AutoMACS) widely used for rare-cell and exosome isolation in research and clinical settings; overlaps with BioFluidica's LiquidScan in target customers and application.

TypeDirect peer
Description

Develops the AccuCyte and CytePicker platforms for CTC enumeration and retrieval from blood; competes head-to-head with LiquidScan in the rare-cell liquid biopsy research market.

TypeDirect peer
Description

Markets the Parsortix microfluidic system for capturing CTCs from blood for downstream analysis; another direct competitor in antibody-independent microfluidic rare-cell capture, with overlap in oncology research applications.

TypeDirect peer
Description

Provides exosome/EV isolation reagents (ExoQuick, Exo-spin) and analytical tools widely used in liquid biopsy research; competes with BioFluidica's pillar-chip exosome isolation in research-use workflows.

TypeBroad incumbent
Description

Broad life-science and molecular diagnostics incumbent with liquid biopsy sample-prep kits (e.g., QIAamp circulating nucleic acid kits) and the QIAcuity digital PCR platform; competes as part of a much larger portfolio serving overlapping customers.

TypeBroad incumbent
Description

Sells laboratory automation (KingFisher, Ion Torrent) and a wide range of liquid biopsy reagents; relevant because BioFluidica's LiquidScan STAR(let) integrates with Hamilton robots and competes for the same lab budgets.

TypeEmerging player
Description

Provides microfluidics-based single-cell and biomarker analysis platforms with overlap in microfluidics expertise and liquid biopsy research customers, though its primary focus is broader multi-omics rather than CTC/exosome isolation.

TypeDirect peer
Description

Leader in cell-free DNA-based non-invasive prenatal testing (Panorama) and oncology liquid biopsy (Signatera); a direct competitor in the prenatal diagnostics market that BioFluidica's cbNIPT aims to enter with a cell-based (rather than cfDNA-based) approach.

TypeBroad incumbent
Description

Dominant liquid biopsy company in oncology with Guardant360 and Reveal tests; competes in oncology liquid biopsy broadly, though its cfDNA-centric approach contrasts with BioFluidica's rare-cell and exosome focus.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BioFluidica

Liquid Biopsy Diagnosticsbiofluidica.com

BioFluidica is a privately held biotechnology company that has developed the LiquidScan microfluidics-based liquid biopsy platform, which isolates and enriches rare cells and exosomes from bodily fluids for oncology and prenatal diagnostics researchers.

What BioFluidica does

BioFluidica is a privately held biotechnology company that has developed the LiquidScan® platform, a microfluidics-based liquid biopsy system that isolates and enriches rare cells — including circulating tumor cells (CTCs) and fetal trophoblasts — and exosomes/extracellular vesicles from whole blood, plasma, urine, and saliva. The platform centers on proprietary antibody-surfaced microfluidic chips (sinusoidal for rare-cell capture, pillar for exosome subpopulations) combined with a catch-and-release chemistry using photoactivated (415 nm) or heat-activated enzymatic cleavable linkers, integrated onto Hamilton Microlab STAR/STARlet liquid handling robots via proprietary automation software.

The company sells three product lines: LiquidScan instruments installed at customer facilities, one-time-use consumable microfluidic chips and reagent kits (4- or 8-chip formats), and fee-for-service testing from its San Diego Core Lab. Pricing is quote-based and not publicly disclosed. Its primary customer segments are oncology researchers and clinicians (covering nine-plus cancer types including ovarian, colorectal, lung, pancreatic, and leukemia) and prenatal diagnostics researchers pursuing cell-based NIPT, with secondary reach into academic research institutions and immunotherapy developers. Named customers include the University of Kansas Medical Center, which has run LiquidScan systems continuously since 2022.

BioFluidica operates from three U.S. locations: a world headquarters in Cary, North Carolina; the Central Innovation Lab in Lawrence, Kansas; and a San Diego Core Facility. Leadership includes Co-Founder and CTO Dr. Steven A. Soper (Foundation Distinguished Professor at Kansas University, 310+ peer-reviewed publications, three-time NAI Fellow) and CEO Greg Studdard (former executive at GeneCare/Alere and Verinata Health, which was acquired by Illumina in 2013). The company raised over $6 million in a Series B2 round in February 2022 (with closings anticipated to $10M) and received MBArC/NIH RADx Tech grant funding to extend the platform toward handheld at-home disease testing. LiquidScan is currently labeled for Research Use Only; no FDA-cleared clinical diagnostic product has been disclosed.

BioFluidica firmographics

Firmographics
Name
BioFluidica
Legal name
BioFluidica, Inc.
Website
https://biofluidica.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
1–10 employees
Short description
BioFluidica is a privately held biotechnology company that has developed the LiquidScan microfluidics-based liquid biopsy platform, which isolates and enriches rare cells and exosomes from bodily fluids for oncology and prenatal diagnostics researchers.
Ownership category
akta.pro rank

BioFluidica industry classification

Industry
Product category
Liquid Biopsy Diagnostics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAAMAH
Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAHAAAN
Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHDAHALAK
Biosensors & Lab-on-Chip (BioMEMS)

Keywords

  • Liquid biopsy platform
  • Microfluidic diagnostics
  • Rare cell isolation
  • Exosome isolation
  • Circulating tumor cells

Where BioFluidica is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices3 records

Markets served

BioFluidica business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. LiquidScan Instrument Sales: Sale of LiquidScan processing module and reagent kits for installation in customer facilities (research institutions, clinical labs). The system is sold with associated microfluidic chips and reagents.
  2. Fee-for-Service Testing: BioFluidica offers services from their Core Labs on a fee-for-service basis, performing complete studies or pilot projects for customers who prefer not to operate their own systems.
  3. Reagent Kit Sales: Sale of reagent plates, microfluidic chips (4 or 8 per kit), sample tubes, and waste tubes. Reagent kits are one-time-use consumables that must be repurchased for each run.

Pricing tiers

ModelBillingPrice
One time/ perpetual licenseMulti-year contractLiquidScan System - For installation in customer facilities
OtherPay-as-you-goFee-for-Service Core Lab Testing
Unit PricingPay-as-you-goReagent Kits (4 or 8 chips)

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

BioFluidica product offering

Product offering

Core offering

BioFluidica develops and sells the LiquidScan® platform, a fully automated microfluidic system for isolating and enriching rare cells (circulating tumor cells, fetal trophoblasts) and exosomes from liquid biopsy samples including whole blood, plasma, urine, and saliva. The platform pairs proprietary antibody-surfaced microfluidic chips with a Hamilton Microlab STAR/STARlet liquid handling robot and uses catch-and-release cleavable-linker chemistry to release intact analytes compatible with downstream molecular analysis. The company also offers reagent kits, one-time-use microfluidic chips, and fee-for-service testing from its San Diego Core Lab.

Product overview

BioFluidica offers the LiquidScan® platform as its core product line, comprising an automated system (LiquidScan STAR(let)) that processes one-time-use microfluidic chips and reagent kits to isolate and enrich rare cells (CTCs, trophoblasts) and exosomes from liquid biopsy samples. The platform supports whole blood, plasma, urine, and saliva samples and produces output compatible with downstream molecular analysis methods including NGS, RNA-Seq, ddPCR, and qPCR. Additionally, BioFluidica is developing a Fetal Cell-Based DNA Test for prenatal diagnostics.

Differentiator

Problem solved

Functional benefit

Brands

  • LiquidScan®: A fully-automated liquid biopsy platform for isolating and enriching rare cells (CTCs, trophoblasts) and exosomes from liquid biopsy samples using microfluidic chip technology.

Products and services

  • LiquidScan Automated System Fully automated walk-away system for isolating and enriching rare cells and exosomes from liquid biopsy samples (whole blood, plasma, urine, saliva). Integrates with a Hamilton Microlab STAR or STARlet liquid handling robot and uses proprietary antibody-surfaced microfluidic chips with catch-and-release cleavable-linker chemistry. Used by oncology and prenatal researchers, academic core facilities, and pharmaceutical R&D teams.
  • LiquidScan Microfluidic Chips One-time-use test-specific microfluidic devices with antibody-surfaced channels for capture, isolation, and enrichment of rare cells or exosomes. Available in sinusoidal (rare-cell) and pillar (exosome) chip formats. Chips can process 1-8 simultaneously. Sold as part of reagent kits to customers operating the LiquidScan system.
  • LiquidScan Reagent Kits Reagent plate with contents ready to process 4 or 8 microfluidic chips, including antibody-surfaced chips, sample tubes, and waste/re-process sample tubes. One-time-use test-specific consumables that must be repurchased for each run.
  • Fee-for-Service Core Lab Testing BioFluidica performs complete studies or pilot projects on a fee-for-service basis from its San Diego Core Facility for customers who prefer not to operate their own LiquidScan systems. Offers whole-blood, plasma, urine, and saliva sample processing for rare cell and exosome isolation.

Quantifiable outcome

  • Captures rare cells at concentrations of 1-10 CTCs/ml in blood with high efficiency
  • +3 more outcomes

Companies that use BioFluidica

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles4 records

BioFluidica technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

BioFluidica partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • University of Kansas Medical CentercoreStrategic or Co-development Partner · 1 January 2022BioFluidica equipped the liquid biopsy core facility at KUMC with LiquidScan systems to serve their clinical research needs. The systems have been continuously operating since 2022, testing applications and evolving user protocols. This partnership enables clinical validation and provides reference site for technology demonstration.

Scale indicators5 records

Recent moves5 records

Expansion highlights7 records

BioFluidica competitors and assessment

Company assessment

Direct peers

  • Menarini Silicon Biosystems: Offers the CELLSEARCH CTC system and DEPArray for rare-cell isolation and downstream molecular analysis; directly competes with BioFluidica in circulating tumor cell capture and downstream characterization for liquid biopsy research and clinical use.
  • Miltenyi Biotec: Provides microfluidic and magnetic-bead-based cell separation platforms (e.g., MACS, AutoMACS) widely used for rare-cell and exosome isolation in research and clinical settings; overlaps with BioFluidica's LiquidScan in target customers and application.
  • RareCyte: Develops the AccuCyte and CytePicker platforms for CTC enumeration and retrieval from blood; competes head-to-head with LiquidScan in the rare-cell liquid biopsy research market.
  • ANGLE plc: Markets the Parsortix microfluidic system for capturing CTCs from blood for downstream analysis; another direct competitor in antibody-independent microfluidic rare-cell capture, with overlap in oncology research applications.
  • Bio-Techne: Provides exosome/EV isolation reagents (ExoQuick, Exo-spin) and analytical tools widely used in liquid biopsy research; competes with BioFluidica's pillar-chip exosome isolation in research-use workflows.
  • Natera: Leader in cell-free DNA-based non-invasive prenatal testing (Panorama) and oncology liquid biopsy (Signatera); a direct competitor in the prenatal diagnostics market that BioFluidica's cbNIPT aims to enter with a cell-based (rather than cfDNA-based) approach.

Broad incumbents

  • QIAGEN: Broad life-science and molecular diagnostics incumbent with liquid biopsy sample-prep kits (e.g., QIAamp circulating nucleic acid kits) and the QIAcuity digital PCR platform; competes as part of a much larger portfolio serving overlapping customers.
  • Thermo Fisher Scientific: Sells laboratory automation (KingFisher, Ion Torrent) and a wide range of liquid biopsy reagents; relevant because BioFluidica's LiquidScan STAR(let) integrates with Hamilton robots and competes for the same lab budgets.
  • Guardant Health: Dominant liquid biopsy company in oncology with Guardant360 and Reveal tests; competes in oncology liquid biopsy broadly, though its cfDNA-centric approach contrasts with BioFluidica's rare-cell and exosome focus.

Emerging players

  • Standard BioTools (formerly Fluidigm): Provides microfluidics-based single-cell and biomarker analysis platforms with overlap in microfluidics expertise and liquid biopsy research customers, though its primary focus is broader multi-omics rather than CTC/exosome isolation.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

BioFluidica social profiles

Digital presence

BioFluidica financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BioFluidica leadership team

Management profile

Number of profiles

Profiles6 records

BioFluidica funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BioFluidica M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioFluidica

What does BioFluidica do?

BioFluidica develops and sells the LiquidScan® platform, a fully automated microfluidic system for isolating and enriching rare cells (circulating tumor cells, fetal trophoblasts) and exosomes from liquid biopsy samples including whole blood, plasma, urine, and saliva. The platform pairs proprietary antibody-surfaced microfluidic chips with a Hamilton Microlab STAR/STARlet liquid handling robot and uses catch-and-release cleavable-linker chemistry to release intact analytes compatible with downstream molecular analysis. The company also offers reagent kits, one-time-use microfluidic chips, and fee-for-service testing from its San Diego Core Lab.

Is BioFluidica a public or private company?

BioFluidica is a private company. It is classified as venture growth investor backed and is currently operating.

When was BioFluidica founded?

BioFluidica was founded in 2013. It employs 1 to 10 people.

Where is BioFluidica based?

BioFluidica is headquartered in San Diego, United States, in the North America region.

How does BioFluidica make money?

Three revenue lines are on record. LiquidScan Instrument Sales are the primary driver. The others are fee-for-Service Testing and reagent Kit Sales.

Who are BioFluidica's main competitors?

Direct peers on record are Menarini Silicon Biosystems, Miltenyi Biotec, RareCyte, ANGLE plc, Bio-Techne and Natera. Broad incumbents are QIAGEN, Thermo Fisher Scientific and Guardant Health. Standard BioTools (formerly Fluidigm) is listed as an emerging player.

Does BioFluidica have an API?

No public API is recorded for BioFluidica.

What industry is BioFluidica in?

BioFluidica's product category is Liquid Biopsy Diagnostics. Its primary akta.pro industry code is HLAAAMAH, Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes), with a secondary code of HLAHAAAN, Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics). Its NAICS code is 541714 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
WalkersfuneralservicePhilip Dean Buchanan Obituary May 22, 2026Philip Dean Buchanan, a pioneering cytogeneticist, passed away, leaving a significant legacy in the field of medical genetics. He founded Genetics Associates, which later became the GeneCare Medical Genetics Center, and received numerous accolades for his contributions. His influence extended beyond genetics, as he served on the boards of Voices Together and Biofluidica, championing innovative approaches in healthcare.PR NewswireBioFluidica Next-Generation Liquid Biopsy Platform Uncovers Undiagnosed HER2+ PatientsBioFluidica announced results from a pilot breast cancer study (n=16) demonstrating that their non-invasive LiquidScan liquid biopsy platform detected over 25% more HER2+ patients who may be eligible for targeted therapy compared to traditional needle biopsies. The study was conducted in collaboration with NeoGenomics Laboratories and researchers at UCSD Moores Cancer Center, with findings scheduled for presentation at the Precision Medicine World Conference 2022. The company is preparing a larger follow-up study to better validate patient profiling using the blood-based analysis platform.PR NewswireBioFluidica to Introduce Next-Generation Biomarker Isolation PlatformBioFluidica, Inc. announced the introduction of its new biomarker isolation platform, LiquidScan, at the 2022 American Association for Cancer Research Meeting in New Orleans. The platform utilizes microfluidics to isolate biomarkers from blood samples, aiming to replace surgical biopsies and enable non-invasive diagnostic testing for various diseases. This development offers potential benefits such as lower costs, high-throughput analysis, and improved patient monitoring without requiring cold storage.TrialstatBioFluidica Extends NIH Award through the Midwest Biomedical Accelerator Research Consortium for an At-Home Device Using Breakthrough Technology in the Fight Against COVID-19BioFluidica has secured a continuation grant from the Midwest Biomedical Accelerator Research Consortium on behalf of the NIH's RADx Tech program to support the development of its LiquidScan handheld device. The platform utilizes patented microfluidic technology to provide rapid, at-home diagnostic testing for diseases like COVID-19 with results in 15 minutes. The automated benchtop version of LiquidScan is currently entering commercialization and will be showcased at the AACR 2022 conference.SdbnBioFluidica Extends NIH Award through the Midwest Biomedical Accelerator Research Consortium for an At-Home Device Using Breakthrough Technology in the Fight Against COVID-19 – San Diego BiotechnologyBioFluidica, a privately held biotechnology company, announced on March 23, 2022 that it has been awarded a continuation grant from the Midwest Biomedical Accelerator Research Consortium. The grant supports its LiquidScan Next-Generation Testing Platform, which the company says can detect diseases in 15 minutes. The announcement did not disclose the grant amount or the specific disease targets.PR NewswireBioFluidica Extends NIH Award through the Midwest Biomedical Accelerator Research Consortium for an At-Home Device Using Breakthrough Technology in the Fight Against COVID-19BioFluidica received a continuation grant from the Midwest Biomedical Accelerator Research Consortium on behalf of the NIH's RADx Tech program to further develop its LiquidScan handheld device for at-home COVID-19 testing. The platform utilizes patented microfluidic technology to detect diseases in 15 minutes with high sensitivity, aiming to provide lower-cost, rapid diagnostics for various conditions including cancer and infectious diseases.Med IndiaBioFluidica Extends NIH Award through the Midwest Biomedical Accelerator Research Consortium for an At-Home Device Using Breakthrough Technology in the Fight AgBioFluidica has secured a continuation grant from the Midwest Biomedical Accelerator Research Consortium on behalf of the NIH RADx Tech program to support the development of its LiquidScan handheld device. This at-home diagnostic tool utilizes microfluidic technology to detect diseases like COVID-19 in 15 minutes with qPCR-level sensitivity, aiming to provide faster and more accessible testing than traditional laboratory methods.citybizBioFluidica Raises $6 Million Series B2BioFluidica, Inc. announced the initial closing of over $6 million in its Series B2 financing round, with additional closings anticipated to reach a total target of $10 million. The funding, led by existing investors with participation from new ones, will support the commercialization of its LiquidScan™ platform and the development of a handheld infectious disease detection device. This investment supplements support from the National Institutes of Health’s RADx initiative to advance low-cost, high-sensitivity at-home Covid-detection.PR NewswireBioFluidica™ Announces Promising New Data for Identifying Fetal Aneuploidy Using the LiquidScan™, a High Throughput Liquid Biopsy Platform.BioFluidica announced promising new data published in the journal Prenatal Diagnosis showing their LiquidScan™ microfluidic platform can successfully identify fetal chromosome abnormalities (aneuploidies) by isolating circulating trophoblasts from maternal blood samples. The study tested samples from nine pregnant women with confirmed fetal abnormalities and correctly identified five types of aneuploidies in all samples regardless of gestational age or maternal weight. The company claims this cell-based non-invasive prenatal test could offer wider diagnostic potential than currently available cell-free DNA screening methods.